<?xml version='1.0' encoding='utf-8'?>
<document id="28255849"><sentence text="Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis."><entity charOffset="31-41" id="DDI-PubMed.28255849.s1.e0" text="Cladribine" /></sentence><sentence text="The aims of this study were to characterize the concentration-time course of cladribine (CdA) and its main metabolite 2-chloroadenine (CAde), estimate interindividual variability in pharmacokinetics (PK), and identify covariates explaining variability in the PK of CdA"><entity charOffset="77-87" id="DDI-PubMed.28255849.s2.e0" text="cladribine" /><entity charOffset="89-92" id="DDI-PubMed.28255849.s2.e1" text="CdA" /><entity charOffset="118-133" id="DDI-PubMed.28255849.s2.e2" text="2-chloroadenine" /><entity charOffset="135-139" id="DDI-PubMed.28255849.s2.e3" text="CAde" /><entity charOffset="265-268" id="DDI-PubMed.28255849.s2.e4" text="CdA" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e0" e2="DDI-PubMed.28255849.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e0" e2="DDI-PubMed.28255849.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e0" e2="DDI-PubMed.28255849.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e0" e2="DDI-PubMed.28255849.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e0" e2="DDI-PubMed.28255849.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e1" e2="DDI-PubMed.28255849.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e1" e2="DDI-PubMed.28255849.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e1" e2="DDI-PubMed.28255849.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e1" e2="DDI-PubMed.28255849.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e2" e2="DDI-PubMed.28255849.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e2" e2="DDI-PubMed.28255849.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e2" e2="DDI-PubMed.28255849.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e3" e2="DDI-PubMed.28255849.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s2.e3" e2="DDI-PubMed.28255849.s2.e4" /></sentence><sentence text="" /><sentence text="This population PK analysis was based on the combined dataset from four clinical studies in patients with multiple sclerosis (MS): three phase I studies, including one food and one drug-drug interaction study, and one phase III clinical study" /><sentence text=" Plasma and urine concentration data of CdA and CAde were modeled simultaneously"><entity charOffset="40-42" id="DDI-PubMed.28255849.s5.e0" text="CdA" /><entity charOffset="48-50" id="DDI-PubMed.28255849.s5.e1" text="CAde" /><pair ddi="false" e1="DDI-PubMed.28255849.s5.e0" e2="DDI-PubMed.28255849.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28255849.s5.e0" e2="DDI-PubMed.28255849.s5.e1" /></sentence><sentence text="" /><sentence text="The analysis comprised a total of 2619 CdA and CAde plasma and urine concentration observations from 173 patients with MS who received an intravenous infusion or oral tablet doses of CdA as a single agent or in combination with interferon (IFN) β-1a"><entity charOffset="39-42" id="DDI-PubMed.28255849.s7.e0" text="CdA" /><entity charOffset="183-186" id="DDI-PubMed.28255849.s7.e1" text="CdA" /><entity charOffset="47-50" id="DDI-PubMed.28255849.s7.e2" text="CAde" /><pair ddi="false" e1="DDI-PubMed.28255849.s7.e0" e2="DDI-PubMed.28255849.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28255849.s7.e0" e2="DDI-PubMed.28255849.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s7.e0" e2="DDI-PubMed.28255849.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s7.e2" e2="DDI-PubMed.28255849.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s7.e2" e2="DDI-PubMed.28255849.s7.e1" /></sentence><sentence text=" CdA PK data were best described by a three-compartment model, while a one-compartment model best described the PK of CAde"><entity charOffset="1-4" id="DDI-PubMed.28255849.s8.e0" text="CdA" /><entity charOffset="118-121" id="DDI-PubMed.28255849.s8.e1" text="CAde" /><pair ddi="false" e1="DDI-PubMed.28255849.s8.e0" e2="DDI-PubMed.28255849.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28255849.s8.e0" e2="DDI-PubMed.28255849.s8.e1" /></sentence><sentence text=" CdA renal clearance (CLR) was correlated with creatinine clearance (CLCR), predicting a decrease in the total clearance of 19%, 30% and 40% for patients with mild (CLCR = 65 ml/min), moderate (CLCR = 40 ml/min) and severe (CLCR = 20 ml/min) renal impairment, respectively"><entity charOffset="47-57" id="DDI-PubMed.28255849.s9.e0" text="creatinine" /><entity charOffset="1-10" id="DDI-PubMed.28255849.s9.e1" text="CdA" /><pair ddi="false" e1="DDI-PubMed.28255849.s9.e1" e2="DDI-PubMed.28255849.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s9.e1" e2="DDI-PubMed.28255849.s9.e0" /></sentence><sentence text=" Food decreased the extent of CdA absorption by 11"><entity charOffset="30-32" id="DDI-PubMed.28255849.s10.e0" text="CdA" /></sentence><sentence text="2% and caused an absorption delay" /><sentence text=" Coadministration with IFNβ-1a was found to increase non-CLR (CLNR) by 21%, resulting in an increase of 11% in total clearance" /><sentence text="" /><sentence text="Both CdA and CAde displayed linear PK after intravenous and oral administration of CdA, with CdA renal function depending on CLCR"><entity charOffset="5-7" id="DDI-PubMed.28255849.s14.e0" text="CdA" /><entity charOffset="83-85" id="DDI-PubMed.28255849.s14.e1" text="CdA" /><entity charOffset="93-95" id="DDI-PubMed.28255849.s14.e2" text="CdA" /><entity charOffset="13-15" id="DDI-PubMed.28255849.s14.e3" text="CAde" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e0" e2="DDI-PubMed.28255849.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e0" e2="DDI-PubMed.28255849.s14.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e0" e2="DDI-PubMed.28255849.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e0" e2="DDI-PubMed.28255849.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e3" e2="DDI-PubMed.28255849.s14.e3" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e3" e2="DDI-PubMed.28255849.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e3" e2="DDI-PubMed.28255849.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e1" e2="DDI-PubMed.28255849.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28255849.s14.e1" e2="DDI-PubMed.28255849.s14.e2" /></sentence><sentence text=" Trial registration number for study 25643: NCT00213135" /><sentence text="" /></document>